June 12, 2020<\/p>\n\n\n\n
Royalty Pharma and Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases announced that Agios has sold its tiered, sales-based royalty rights on worldwide net sales of Bristol Myers Squibb\u2019s IDHIFA\u00ae (enasidenib), as well as its rights to receive up to $55 million in outstanding regulatory milestone payments from Bristol Myers Squibb, to Royalty Pharma for $255 million. Agios will continue to co-promote IDHIFA\u00ae and receive reimbursement from Bristol Myers Squibb for this co-promotion under its 2010 collaboration agreement with Celgene, a wholly owned subsidiary of Bristol Myers Squibb. IDHIFA\u00ae is an oral, targeted therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation.<\/p>\n\n\n\n
[\u2026]<\/p>\n\n\n\n
Cowen served as financing advisor to Agios and Wilmer Hale served as legal advisor to Agios. Goodwin Procter LLP, Dechert LLP and Maiwald Patentanwalts- und Rechtsanwaltsgesellschaft mbH acted as legal advisors to Royalty Pharma on the transaction.<\/p>\n\n\n\n
This text is a press release from Royalty Pharma. The full text version of the article can be found here: https:\/\/www.royaltypharma.com\/news-releases\/news-release-details\/royalty-pharma-acquires-rights-agios-royalty-idhifar-worldwide<\/a> <\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-23313","presseberichte","type-presseberichte","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte\/23313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte"}],"about":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/types\/presseberichte"}],"version-history":[{"count":0,"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte\/23313\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/media?parent=23313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}